Summary
ABL Chart
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib).
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
Abbott Laboratories Dividends
 ABL 6 months ago | Other | €0.55 Per Share |
| ABL 9 months ago | Other | €0.55 Per Share |
| ABL 12 Apr 2024 | Other | €0.55 Per Share |
| ABL 11 Jan 2024 | Other | €0.55 Per Share |
| ABL 12 Oct 2023 | Other | €0.51 Per Share |
Abbott Laboratories Earnings
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 22 Jan 2025 Date | | - Cons. EPS | - EPS |
| 16 Oct 2024 Date | | - Cons. EPS | - EPS |
| 18 Jul 2024 Date | | - Cons. EPS | - EPS |
| 26 Apr 2024 Date | | - Cons. EPS | - EPS |
| ABL 6 months ago | Other | €0.55 Per Share |
| ABL 9 months ago | Other | €0.55 Per Share |
| ABL 12 Apr 2024 | Other | €0.55 Per Share |
| ABL 11 Jan 2024 | Other | €0.55 Per Share |
| ABL 12 Oct 2023 | Other | €0.51 Per Share |
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 22 Jan 2025 Date | | - Cons. EPS | - EPS |
| 16 Oct 2024 Date | | - Cons. EPS | - EPS |
| 18 Jul 2024 Date | | - Cons. EPS | - EPS |
| 26 Apr 2024 Date | | - Cons. EPS | - EPS |
Abbott Laboratories (ABL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Abbott Laboratories ever had a stock split?
Abbott Laboratories Profile
| Medical Devices Industry | Healthcare Sector | Mr. Robert B. Ford CEO | XDUS Exchange | US0028241000 ISIN |
| United States Country | 114,000 Employees | 15 Apr 2025 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Overview
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Products and Services
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains:
- Generic Pharmaceuticals: Includes treatments for pancreatic exocrine insufficiency, irritable bowel syndrome, biliary spasm, intrahepatic cholestasis, depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease, vestibular vertigo, pain, fever, inflammation, migraine, anti-infective clarithromycin, influenza vaccine, and colon rhythm regulation products.
- Diagnostic Products: Offers laboratory and transfusion medicine systems in areas such as immunoassay, clinical chemistry, hematology, and transfusion. Includes molecular diagnostics for DNA and RNA processing and detection of infectious agents, point-of-care systems, blood gas testing cartridges, rapid diagnostics, molecular point-of-care testing for several diseases, cardiometabolic tests, drug and alcohol tests, remote patient monitoring, consumer self-tests, and laboratory automation and informatics solutions.
- Nutritional Products: Provides nutritional products for both pediatric and adult use, catering to the specific dietary needs of different age groups and health conditions.
- Medical Devices: Offers a wide array of devices for the treatment of cardiovascular diseases, including rhythm management, electrophysiology, heart failure, vascular, and structural heart devices. Additionally, the company develops diabetes care products such as blood glucose monitoring systems, along with neuromodulation devices for managing chronic pain and movement disorders.
Contact Information
